JP2025502064A - フリードライヒ運動失調症を治療するための化合物及び方法 - Google Patents

フリードライヒ運動失調症を治療するための化合物及び方法 Download PDF

Info

Publication number
JP2025502064A
JP2025502064A JP2024540893A JP2024540893A JP2025502064A JP 2025502064 A JP2025502064 A JP 2025502064A JP 2024540893 A JP2024540893 A JP 2024540893A JP 2024540893 A JP2024540893 A JP 2024540893A JP 2025502064 A JP2025502064 A JP 2025502064A
Authority
JP
Japan
Prior art keywords
optionally substituted
methyl
alkyl
pharma
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502064A5 (cg-RX-API-DMAC7.html
Inventor
アンサリ,アシーム
バット,アビジット
ジェフリーズ,ショーン
シャー,プラティック
ジャン,チェンジ
Original Assignee
デザイン セラピューティクス,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デザイン セラピューティクス,インク. filed Critical デザイン セラピューティクス,インク.
Publication of JP2025502064A publication Critical patent/JP2025502064A/ja
Publication of JP2025502064A5 publication Critical patent/JP2025502064A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2024540893A 2022-01-06 2023-01-06 フリードライヒ運動失調症を治療するための化合物及び方法 Pending JP2025502064A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263297090P 2022-01-06 2022-01-06
US63/297,090 2022-01-06
US202263382854P 2022-11-08 2022-11-08
US63/382,854 2022-11-08
PCT/US2023/010331 WO2023133284A2 (en) 2022-01-06 2023-01-06 Compounds and methods for treating friedreich's ataxia

Publications (2)

Publication Number Publication Date
JP2025502064A true JP2025502064A (ja) 2025-01-24
JP2025502064A5 JP2025502064A5 (cg-RX-API-DMAC7.html) 2026-01-06

Family

ID=87074158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540893A Pending JP2025502064A (ja) 2022-01-06 2023-01-06 フリードライヒ運動失調症を治療するための化合物及び方法

Country Status (14)

Country Link
US (1) US20250109132A1 (cg-RX-API-DMAC7.html)
EP (1) EP4460302A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025502064A (cg-RX-API-DMAC7.html)
KR (1) KR20240138079A (cg-RX-API-DMAC7.html)
AU (1) AU2023205889A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246468A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002029A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010651A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240321A (cg-RX-API-DMAC7.html)
IL (1) IL314006A (cg-RX-API-DMAC7.html)
MX (1) MX2024008474A (cg-RX-API-DMAC7.html)
PE (1) PE20241730A1 (cg-RX-API-DMAC7.html)
TW (1) TW202334148A (cg-RX-API-DMAC7.html)
WO (1) WO2023133284A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116490507A (zh) 2020-09-10 2023-07-25 薛定谔公司 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
WO2025076181A1 (en) * 2023-10-03 2025-04-10 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease
EP4788669A1 (en) * 2023-10-03 2026-08-12 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease
WO2025076219A1 (en) * 2023-10-03 2025-04-10 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2015053413A1 (ja) * 2013-10-11 2015-04-16 千葉県 ドライバーオンコジーンの遺伝子変異を標的にアルキル化する新規アルキル化剤
US11759533B2 (en) * 2017-03-29 2023-09-19 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
WO2020253711A1 (zh) * 2019-06-17 2020-12-24 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
JP7465945B2 (ja) * 2019-07-02 2024-04-11 ニューベイション・バイオ・インコーポレイテッド Bet阻害剤としてのヘテロ環式化合物
CA3204523A1 (en) * 2021-01-08 2022-07-14 Aseem Ansari Methods and compounds for treating friedreich's ataxia

Also Published As

Publication number Publication date
IL314006A (en) 2024-08-01
CR20240321A (es) 2024-10-16
AU2023205889A1 (en) 2024-08-15
CO2024010651A2 (es) 2024-08-08
EP4460302A2 (en) 2024-11-13
US20250109132A1 (en) 2025-04-03
CA3246468A1 (en) 2023-07-13
MX2024008474A (es) 2024-07-12
EP4460302A4 (en) 2025-12-24
WO2023133284A3 (en) 2023-08-24
WO2023133284A2 (en) 2023-07-13
KR20240138079A (ko) 2024-09-20
PE20241730A1 (es) 2024-08-19
CL2024002029A1 (es) 2024-11-04
TW202334148A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
KR20240138079A (ko) 프리드라이히 운동실조를 치료하기 위한 화합물 및 방법
US20240050576A1 (en) Methods and compounds for the treatment of genetic disease
EP4234553A2 (en) Methods and compounds for the treatment of genetic disease
JP6895396B2 (ja) 疾患を処置するためのgls1阻害薬
KR20180128937A (ko) 질환을 치료하는데 유용한 fimh의 만노스-유래 길항제
US20240166693A1 (en) Methods and compounds for modulating myotonic dystropy 1
JP2025512877A (ja) ハンチントン病を調節するための方法及び化合物
JP2024502469A (ja) フリードライヒ運動失調症を治療するための方法及び化合物
EP4234550A2 (en) Methods and compounds for the treatment of genetic disease
US20230285569A1 (en) Methods and compounds for the treatment of fragile x
CN118695861A (zh) 用于治疗弗里德希共济失调的化合物和方法
HK40116639A (en) Compounds and methods for treating friedreich's ataxia
EA049760B1 (ru) Соединения и способы лечения атаксии фридрейха
HK40104905A (en) Methods and compounds for modulating myotonic dystrophy 1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251222